News 2022-03-11
Porton Announced to Acquire China Gateway Pharmaceutical Development Co., Ltd.
Expand small and medium-scale CDMO production capacity
March 10th, 2022, Shanghai · China - Porton Pharma Solutions Ltd. announced that it is to acquire 100% equity of China Gateway Pharmaceutical Development Co., Ltd. (referred to as "Gateway Pharmaceutical"), a CDMO platform under ChemPartner PharmaTech Co., Ltd.
Gateway Pharmaceutical is located at Fengxian District, Shanghai. The site covers a total area of about 64,480m2. The first phase of the project covering an area of about 32,495 m2 has been completed and put into use. There is currently a pilot workshop with the capacity of 72m³, a number of process development laboratories and kilogram laboratories with an area of 14,500 m2, an office building, warehouses and other auxiliary facilities.
The acquisition of Gateway Pharmaceutical will be an effective supplement to Porton's CRO capability. In addition, with the help of the geographical coordination between Gateway Pharmaceutical and Porton Shanghai R&D Center, the CRO project can achieve efficient linkage of R&D and production. We welcome Gateway Pharmaceutical to join Porton and expect that it will support further implementation of Porton's end-to-end CDMO strategy through further integration in governance, operations, and business.
The signing ceremony was held today in the Fengxian site of Gateway Pharmaceutical.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
